Filing Flows › Autolus Therapeutics (AUTL) › Q4 2025
Autolus Therapeutics (AUTL) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 27, 2026
Autolus Therapeutics (AUTL) reported revenue of $24.3M for the fourth quarter 2025 (Q4 2025), up 838-fold from a year earlier and +15% from the quarter before. Operating margin was -298.3%, net loss $90.3M (371.9% of revenue).
Autolus Therapeutics, Q4 2025: revenue $24.3M (838× year over year), operating margin -298.3%, net loss $90.3M, operating cash flow −$67.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $24.3M | +15% | 838× |
| Operating profit | −$72.5M | — | — |
| Net earnings | −$90.3M | — | — |
| Operating cash flow | −$67.3M | — | — |
What changed
Revenue was $24.3M in Q4 2025, up 83655% year over year and up 15% from the previous quarter. Product revenue, net was the largest line at 96% of revenue.
Operating costs exceeded revenue by $72.5M, an operating margin of -298.3%. Total costs grew 27% against revenue growth of 83655%. The quarter ended with a net loss of $90.3M, wider than the previous quarter's $79.1M loss.
Operating cash flow was −$67.3M. Non-cash charges added back $2.1M of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items added $17.4M. Capital expenditures of −$885K exceeded it, leaving free cash flow of −$66.4M.
Questions
What was Autolus Therapeutics' revenue in the fourth quarter 2025?
Autolus Therapeutics (AUTL) reported revenue of $24.3M for the fourth quarter 2025 (Q4 2025), up 838-fold from a year earlier and +15% from the quarter before.
Was Autolus Therapeutics profitable in the fourth quarter 2025?
Operating loss was $72.5M (-298.3% of revenue) and net loss $90.3M.